O’Neill Institute for National and Global Health Law O’Neill Institute for National and Global Health Law
 

Posts tagged AIDS

Updating the Ryan White HIV/AIDS Program for a New Era: Examining critical issues facing this major program in the domestic HIV response

Apr03
2013 Leave a Comment Written by O’Neill Institute

UntitledThis post was written by Jeffrey S. Crowley, Distinguished Scholar and Program Director, NationalHIV/AIDS Initiative at the O’Neill Institute.  Questions may be directed to Jeffrey.crowley@law.georgetown.edu.

This is an exciting and dynamic time in responding to the HIV epidemic.  The United States continues to face a very serious epidemic, with 1.1 million Americans living with HIV and roughly 50,000 people who become newly inflected each year, yet recent developments have led many to conclude that we now have the tools to greatly reduce the scope of the epidemic.  Leading policymakers have even begun talking about working toward an AIDS-free generation.

READ MORE »

Posted in Uncategorized - Tagged , , ,

Our Recent Publications in Global Health Law

Feb06
2013 Leave a Comment Written by O’Neill Institute

2012 was a busy year for us all. Below are some of our most recent publications on Global Health Law. 

Feel free to explore these highlighted works and visit our publications page for additional journals, studies, articles and more.

 

tfc toolkitO’Neill Institute for National and Global Health Law. 2012. Tobacco Industry Strategy in Latin American Courts: A Litigation Guide. Toolkit (Spanish) Toolkit (English)

The ratification of the WHO Framework Convention on Tobacco Control (FCTC) by 15 countries in Latin America has played a central role in generating momentum for strong tobacco control laws at the municipal, provincial and national levels – even in the few countries that have not yet ratified the treaty.

The tobacco industry has correspondingly stepped up two related efforts. First, it is spending substantial resources to sway lawmakers against passing effective tobacco control laws. Second, where its efforts to dilute or weaken tobacco control laws fail, it turns to the courts, often deploying the same or similar arguments based on certain purported “rights.” These “rights” relate to the advertising and marketing of its products, the “rights” of citizens to consume those products in public or occupational spaces, and the “rights” of proprietors and employers to permit such consumption. READ MORE »

Posted in Uncategorized - Tagged , , , , , , , , , , , , , , , , , , , ,

World Health Assembly 2011 Outcomes and United Nations AIDS Review Preview

Jun07
2011 Leave a Comment Written by Eric A. Friedman

Will the world’s premier health organization be able to reform itself to revive its global health leadership in the years ahead? Such was undoubtedly the question on the mind of health officials and civil society from around the world as they attended the 64th World Health Assembly (WHA) last month, the World Health Organization’s annual meeting of its governance body, comprised of all 193 of its Member States.

With WHO reform the marquee item on a crowded agenda that touched on many of the most pressing global health issues, this seemed destined to be a historic WHA.

And in some ways, it was – though at least in part, due to another issue. As the 2003 WHA secured its place in history by adopting the first global health treaty, the Framework Convention on Tobacco Control, and the 2005 WHA adopted the revised International Health Regulations, the 2011 WHA set the stage for greater international cooperation in responding to novel influenza viruses by adopting the Pandemic Influenza Preparedness Framework.

Pandemic Influenza Preparedness Framework

Despite being non-binding, and frankly underwhelming, it does for the first time set up a three-pronged global process of increase access of people in developing countries to vaccines and antiviral medication: 1) voluntary vaccine donations by vaccine manufacturers to a WHO stockpile to be used primarily in developing countries; 2) tiered pricing for vaccines and antivirals, and; 3) technology transfer for vaccines and antivirals. Manufacturers are also expected to contribute financially to support WHO’s global influenza surveillance and response system. READ MORE »

Posted in Global Health, Uncategorized - Tagged , , , , , , , , , , ,

From Science Speaks Blog: Dybul on PEPFAR

Jun07
2011 3 Comments Written by O’Neill Institute

Note: The following is a re-post of the interview by John Donnelly, “Dybul on PEPFAR: ‘The sky was the limit,’” which was originally published on Science Speaks: HIV & TB News on June 2, 2011.  It is re-posted here with permission from Science Speaks.

John Donnelly, Dybul on PEPFAR: ‘The sky was the limit’

Ambassador Mark R. Dybul co-directs the Global Health Law Program at Georgetown University Law Center’s O’Neill Institute for National and Global Health Law, where he is also a Distinguished Scholar. He is the inaugural Global Health Fellow of the George W. Bush Institute. Dybul served as the U.S. Global AIDS Coordinator from 2006 to the end of the George W. Bush administration. In that role, he led the implementation of the President’s Emergency Plan for AIDS Relief (PEPFAR), the largest international health initiative in history for a single disease. Prior to assuming the post of ambassador, he was acting, deputy and assistant coordinator, and was a member of the Planning Task Force that created PEPFAR.  Dybul also led President Bush’s International Prevention of Mother and Child HIV initiative for the Department of Health and Human Services (HHS).

Dybul spoke with John Donnelly about the start of PEPFAR and some of the most memorable moments directing it, continuing Science Speaks’ series on 30 years of AIDS.

How did you first get involved in AIDS?
When I was in college, I was trying to decide whether to do a doctorate in theology or English, concentrating on poetry. Then I saw an article on AIDS on the cover of Newsweek, and something inside me said I should spend my life on this. I wound up pursuing it by going to medical school.

Later on you began working with Dr. Anthony Fauci. Tell me about that.
I started as a fellow in infectious diseases. The way the National Institutes of Health (NIH) works is, when you become a fellow you know what lab you are going to go into. I wound up accepted at Tony’s lab, and I did basic and clinical immunology and later some virology in his lab. I also started doing research in Africa with Peter Mugyenyi, and saw his programs and also programs run by TASO (The AIDS Service Organization) in Uganda. When Tony was asked by President Bush to think of what we could do on HIV, I was already working on the ground in Africa. READ MORE »

Posted in Global Health, Uncategorized - Tagged , , , , ,

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.
See the full disclaimer and terms of use.